<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115944</url>
  </required_header>
  <id_info>
    <org_study_id>AlmaLasersInc</org_study_id>
    <nct_id>NCT03115944</nct_id>
  </id_info>
  <brief_title>Pro00019086 - Ultra Circumference Reduction</brief_title>
  <official_title>A Multi-Center Pilot Study to Assess the Safety and Efficacy of the vShape Ultra UltraSpeed Handpiece for Abdomen Circumference Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alma Lasers Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alma Lasers Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-Center Pilot Study to Assess the Safety and Efficacy of the VShape Ultra UltraSpeed
      Handpiece for Abdomen Circumference Reduction
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Circumference Reduction as Measured by Skin Fold and Photography</measure>
    <time_frame>4 Treatments over 4 Weeks</time_frame>
    <description>Skin fold measure utilizes caliper and photography utilizes Galaxy medical camera with extrapolation of measuring dot. Last measurement taken 14 days after final treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Circumference Reduction of Abdomen</condition>
  <arm_group>
    <arm_group_label>UltraSpeed Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UltraSpeed ultrasound treatments</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alma vShape Ultra</intervention_name>
    <description>UltraSpeed ultrasound treatment, a series of four treatments</description>
    <arm_group_label>UltraSpeed Treatment</arm_group_label>
    <other_name>UltraSpeed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent to participate in the study.

          -  Female and male subjects, between 18 and 45 years of age at the time of enrollment.

          -  Fitzpatrick Skin Type I to VI.

          -  Fat thickness of at least 1.5 cm in the treated area (measured by calibrated caliper).

          -  BMI interval: BMI between 20 to 30 (normal to overweight, but not obese).

          -  If female, not pregnant or lactating, must be either post-menopausal, surgically
             sterilized, or using a medically acceptable form of birth control at least 3 months
             prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods
             with spermicide or abstinence).

          -  In addition, negative urine pregnancy test as tested before each treatment and at the
             last follow-up visit for women with childbearing potential (e.g., not menopausal).

          -  General good health confirmed by medical history and skin examination of the treated
             area.

          -  Willing to follow the treatment and follow-up schedule and post-treatment care
             instructions.

          -  Willingness to refrain from a change in diet / exercise / medication regimen for the
             entire course of the study.

          -  Willing to have photographs and images taken of the treated areas to be used,
             de-identified in evaluations, publications and presentations.

        Exclusion Criteria:

          -  History of hypertension, ischemic heart disease, valvular heart disease, congestive
             heart failure, pacemaker / defibrillator, abnormal aortic aneurism.

          -  Known hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive
             status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue
             disease.

          -  Having or undergoing any form of treatment for active cancer, or having a history of
             skin cancer or any other cancer in the areas to be treated, including presence of
             malignant or pre-malignant pigmented lesions.

          -  Having any active electrical implant anywhere in the body, such as a pacemaker or an
             internal defibrillator.

          -  Having a permanent implant in the treated area, such as metal plates or an injected
             chemical substance such as silicone.

          -  Having undergone any other surgery in the treated areas within 12 months of treatment
             or during the study, including liposuction.

          -  Previous body contouring procedures in the treatment area within 12 months.

          -  History of skin disease in the treatment area; known tendency to form keloids or poor
             wound healing.

          -  Suffering from significant skin conditions in the treatment areas or inflammatory skin
             conditions, including, but not limited to, open lacerations or abrasions and active
             cold sores or herpes sores prior to treatment (duration of resolution as per the
             Investigator's discretion) or during treatment course.

          -  Skin lesions in the treatment area other than simple nevi on physical examination
             (e.g., atypical nevus, tattoo, abrasions), including depressed scars in the treatment
             area.

          -  Very poor skin quality (i.e., severe laxity).

          -  Abnormal wall diastasis or hernia on physical examination.

          -  Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count
             within the last 3 months.

          -  Obesity (BMI above 30)

          -  Childbirth within the last 12 months or breastfeeding women.

          -  Any acute or chronic condition which, in the opinion of the Investigator may exclude
             the candidate / patient from entry into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AboutSkin Dermatology</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Plastic Surgery</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Brian S. Biesman</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

